Author

L. Gabellier

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Research Focus:protein structure prediction· 1 Approach:statistical model· 1

Frequent Co-Authors

G. Bossis· 3 shared D. Tempe· 2 shared G. Cartron· 2 shared M. De Toledo· 2 shared R. Hallal· 2 shared C. Arenz· 1 shared C. BECHARA· 1 shared C. LEYRAT· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

G. Bossis

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The SUMOylation inhibitor TAK-981 (Subasumstat) triggers IFN-I-dependent activation of Natural Killer cells against Acute Myeloid Leukemias.

R. Hallal, M. De Toledo, D. Tempe, S. Zemiti, L. Coenon, D. Gitenay, S. George, S. Bonnet, L. Gabellier, G. Cartron, M. Pelegrin, M. Villalba, G. Bossis

This paper shows that TAK-981 activates NK cells against AML by inducing IFN-I secretion, enhancing their cytotoxicity and cytokine production.

bioRxiv · Feb 19, 2024 · PreprintCancer Biology

Discovery and mechanism of action of small molecule inhibitors of ceramidases

S. Granier, R. D. Healey, E. Saied, X. Cong, G. Karsai, L. Gabellier, J. Saint-Paul, E. Del Nero, S. Jeannot, M. Drapeau, S. Fontanel, D. Maurel, S. Basu, C. LEYRAT, G. Bossis, , C. Arenz

The paper discovers small molecule inhibitors of alkaline ceramidase 3 using fluorescent substrates and characterizes their mechanism of action.

bioRxiv · Jun 15, 2021Biochemistry

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of Acute Myeloid Leukemias

R. Paolillo, M. Boulanger, P. Gatel, L. Gabellier, D. Tempe, R. Hallal, M. De Toledo, J. Moreaux, H. Baik, E. Gueret, C. Recher, J.-E. Sarry, G. Cartron, M. Piechaczyk, G. Bossis

This study identifies NOX2 as a marker of poor prognosis and a contributor to chemoresistance in AML, showing its upregulation in drug-resistant cells and association with adverse outcomes.

bioRxiv · Mar 4, 2021Cancer Biology